123 related articles for article (PubMed ID: 35983819)
1. A New Promising Pathway in Aggressive Prostate Cancer: Treg/mir-let8c/lin28b.
Akalin I; Erol B; Aslan E; Ozkanli SS; Efiloglu O; Yildirim S; Caskurlu T; Yildirim A; Karaman MI
Arch Esp Urol; 2022 Jun; 75(5):459-466. PubMed ID: 35983819
[TBL] [Abstract][Full Text] [Related]
2. Determination of miRNA expression profile in patients with prostate cancer and benign prostate hyperplasia.
Sancer O; Koşar PA; Tefebaşı MY; Ergün O; Demir M; Koşar A
Turk J Med Sci; 2022 Jun; 52(3):788-795. PubMed ID: 36326314
[TBL] [Abstract][Full Text] [Related]
3. Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone.
Kang HW; Byun YJ; Moon SM; Kim K; Piao XM; Zheng CM; Moon SK; Choi YH; Kim WT; Kim YJ; Lee SC; Yun SJ; Kim WJ
Investig Clin Urol; 2022 Mar; 63(2):238-244. PubMed ID: 35244999
[TBL] [Abstract][Full Text] [Related]
4. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.
Leidinger P; Hart M; Backes C; Rheinheimer S; Keck B; Wullich B; Keller A; Meese E
Tumour Biol; 2016 Aug; 37(8):10177-85. PubMed ID: 26831660
[TBL] [Abstract][Full Text] [Related]
5. Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role.
Cochetti G; Poli G; Guelfi G; Boni A; Egidi MG; Mearini E
Onco Targets Ther; 2016; 9():7545-7553. PubMed ID: 28008272
[TBL] [Abstract][Full Text] [Related]
6. Serum Levels of miR-223-3p and miR-223-5p in Prostate Diseases.
Dülgeroğlu Y; Eroğlu O
Microrna; 2020; 9(4):303-309. PubMed ID: 33155933
[TBL] [Abstract][Full Text] [Related]
7. Deregulation of circ_003912 contributes to pathogenesis of erosive oral lichen planus by via sponging microRNA-123, -647 and -31 and upregulating FOXP3.
Huang Z; Liu F; Wang W; Ouyang S; Sang T; Huang Z; Liao L; Wu J
Mol Med; 2021 Oct; 27(1):132. PubMed ID: 34670484
[TBL] [Abstract][Full Text] [Related]
8. A study of molecular signals deregulating mismatch repair genes in prostate cancer compared to benign prostatic hyperplasia.
Basu S; Majumder S; Bhowal A; Ghosh A; Naskar S; Nandy S; Mukherjee S; Sinha RK; Basu K; Karmakar D; Banerjee S; Sengupta S
PLoS One; 2015; 10(5):e0125560. PubMed ID: 25938433
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA expression profiles in the progression of prostate cancer--from high-grade prostate intraepithelial neoplasia to metastasis.
Leite KR; Tomiyama A; Reis ST; Sousa-Canavez JM; Sañudo A; Camara-Lopes LH; Srougi M
Urol Oncol; 2013 Aug; 31(6):796-801. PubMed ID: 21880514
[TBL] [Abstract][Full Text] [Related]
10. MiR-23a-3p-regulated abnormal acetylation of FOXP3 induces regulatory T cell function defect in Graves' disease.
Zhang D; Qiu X; Li J; Zheng S; Li L; Zhao H
Biol Chem; 2019 Apr; 400(5):639-650. PubMed ID: 30391932
[TBL] [Abstract][Full Text] [Related]
11. Analysis of miR-146a and miR-142-3p as Potential Markers of Freshly Isolated or In Vitro-Expanded Human Treg cells.
Holmstrøm K; Pedersen AE; Gad M
Scand J Immunol; 2017 Feb; 85(2):113-121. PubMed ID: 27943367
[TBL] [Abstract][Full Text] [Related]
12. Special role of Foxp3 for the specifically altered microRNAs in Regulatory T cells of HCC patients.
Chen L; Ma H; Hu H; Gao L; Wang X; Ma J; Gao Q; Liu B; Zhou G; Liang C
BMC Cancer; 2014 Jul; 14():489. PubMed ID: 25000974
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of miR-338-3p impairs Treg-mediated immunosuppression in pemphigus vulgaris by targeting RUNX1.
Xu M; Liu Q; Li S; Zhang W; Huang X; Han K; Li C; Zeng K
Exp Dermatol; 2020 Jul; 29(7):623-629. PubMed ID: 32386260
[TBL] [Abstract][Full Text] [Related]
14. Increased Expression of miR-494 in Serum of Patients with Prostate Cancer and its Potential Diagnostic Value.
Cai B; Peng JH
Clin Lab; 2019 Aug; 65(8):. PubMed ID: 31414754
[TBL] [Abstract][Full Text] [Related]
15. miR-96-5p, miR-134-5p, miR-181b-5p and miR-200b-3p heterogenous expression in sites of prostate cancer versus benign prostate hyperplasia-archival samples study.
Pełka K; Klicka K; Grzywa TM; Gondek A; Marczewska JM; Garbicz F; Szczepaniak K; Paskal W; Włodarski PK
Histochem Cell Biol; 2021 Mar; 155(3):423-433. PubMed ID: 33331954
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA expression profile of primary prostate cancer stem cells as a source of biomarkers and therapeutic targets.
Rane JK; Scaravilli M; Ylipää A; Pellacani D; Mann VM; Simms MS; Nykter M; Collins AT; Visakorpi T; Maitland NJ
Eur Urol; 2015 Jan; 67(1):7-10. PubMed ID: 25234358
[TBL] [Abstract][Full Text] [Related]
17. Detection of miRNAs in urine of prostate cancer patients.
Stuopelytė K; Daniūnaitė K; Jankevičius F; Jarmalaitė S
Medicina (Kaunas); 2016; 52(2):116-24. PubMed ID: 27170485
[TBL] [Abstract][Full Text] [Related]
18. Identification of microRNAs differentially expressed in prostatic secretions of patients with prostate cancer.
Guzel E; Karatas OF; Semercioz A; Ekici S; Aykan S; Yentur S; Creighton CJ; Ittmann M; Ozen M
Int J Cancer; 2015 Feb; 136(4):875-9. PubMed ID: 24976077
[TBL] [Abstract][Full Text] [Related]
19. Dysregulated Serum MiRNA Profile and Promising Biomarkers in Dengue-infected Patients.
Ouyang X; Jiang X; Gu D; Zhang Y; Kong SK; Jiang C; Xie W
Int J Med Sci; 2016; 13(3):195-205. PubMed ID: 26941580
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA expression profile in Treg cells in the course of primary immune thrombocytopenia.
Zhu Y; Zhu H; Xie X; Zheng Z; Ling Y
J Investig Med; 2019 Dec; 67(8):1118-1124. PubMed ID: 31273052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
